Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol's Opdivo/Yervoy Bid Will Show Whether Tumor Mutation Burden Is Ready For Prime Time

Executive Summary

US FDA officials have supported tumor mutation burden as a biomarker, but analysts question whether a subset analysis of CheckMate 227 will be enough to support approval of Bristol's Opdivo/Yervoy combination in first-line lung cancer.

Advertisement

Related Content

Immuno-Oncology Is Making Pharma Step Up Its Diagnostics Game
Merck Hits IO Bullseye With Keytruda Combo In First-line Lung Cancer
Bristol's Opdivo Delivers, But CheckMate 227 Uncertainties Cloud Quarter
A Biomarker For Bristol: Mutation Burden Shows Promise In Small Cell Lung Cancer
Tumor Mutation Burden Biomarker Emerges In Bristol's '026 Lung Cancer Post Mortem

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel